Recent studies suggest that components of the prosurvival signal transduction pathways involving the Ras-mitogen-activated protein kinase (MAPK) can confer an aggressive, apoptosis-resistant phenotype to leukemia cells. In this study, we report that acute promyelocytic leukemia (APL) cells exploit the Ras-MAPK activation pathway to phosphorylate at Ser112 and to inactivate the proapoptotic protein Bad, delaying arsenic trioxide (ATO)-induced apoptosis. Both in APL cell line NB4 and in APL primary blasts, the inhibition of extracellular signalregulated kinases 1/2 (ERK1/2) and Bad phosphorylation by MEK1 inhibitors enhanced apoptosis in ATO-treated cells. We isolated an arsenic-resistant NB4 subline (NB4-As R ), which showed stronger ERK1/2 activity (2.7-fold increase) and Bad phosphorylation (2.4-fold increase) compared to parental NB4 cells in response to ATO treatment. Upon ATO exposure, both NB4 and NB4-As R cell lines doubled protein levels of the death antagonist Bcl-xL, but the amount of free Bcl-xL that did not heterodimerize with Bad was 1.8-fold greater in NB4-As R than in the parental line. MEK1 inhibitors dephosphorylated Bad and inhibited the ATO-induced increase of Bcl-xL, overcoming ATO resistance in NB4-As R . These results may provide a rationale to develop combined or sequential MEK1 inhibitors plus ATO therapy in this clinical setting.
Introduction
It has been demonstrated that low doses (0.06-0.6 mg/km of body weight/day) of arsenic trioxide (ATO) are extremely efficacious in the treatment of relapsed acute promyelocytic leukemia (APL), inducing partial differentiation and promoting apoptosis of malignant promyelocytes. 1 This pilot trial conducted at the Memorial Sloan-Kettering Cancer Center together with a more recent multicenter clinical study 2 confirmed the impressive results obtained by Chinese investigators in early studies on ATO in the treatment of this disease. [3] [4] [5] In particular, the efficacy, safety and limited hematological toxicity of this approach was brought to light. 2 Currently, ATO is considered the treatment of choice for patients with relapsed disease, particularly in patients exposed to all-trans retinoic acid (ATRA) within the prior 12 months. 6 The mechanisms of action of ATO have been investigated both in vivo and in vitro: at low doses (0.1-0.25 mM), ATO induces a partial differentiation in APL cells through degradation of PML-RARa, while at higher doses (0.5-2 mM), this agent inhibits cell growth and induces apoptosis through both PMLRARa-dependent and -independent mechanisms with caspase activation of neoplastic cells. [7] [8] [9] In vitro and in vivo studies have been conducted to evaluate the effect of ATO in combination with ATRA or other biological compounds such as cAMP. The results showed that these associations are more effective than the single agents in inducing differentiation or cell apoptosis. [10] [11] [12] According to recent laboratory studies, the blast cells of most acute myelogenous leukemias (AML) including APL show constitutive activation of extracellular signal-regulated kinases 1/2 (ERK1/2) as well as of the kinases immediately upstream of ERK, known as mitogen-activated protein (MAP)/ERK kinases (MEKs). [13] [14] [15] [16] Furthermore, we and others have demonstrated that downmodulation of MEK1 phosphorylation inhibits proliferation and induces apoptosis of primary AML blasts [17] [18] [19] [20] (reviewed in Platanias 21 and Lee and McCubrey 22 ). In this study, we aimed at investigating whether the combination of ATO with agents that block the phosphorylation of MEK1 can potentiate the antileukemic action of ATO in APL. Moreover, blocking MEK1 function with specific inhibitors or specific double-stranded RNA oligonucleotides (siRNA) restored ATO sensitivity in an NB4 cell line rendered resistant to ATO-induced apoptosis. Finally, we demonstrated here that the downmodulation of MEK1 phosphorylation significantly enhanced ATO-induced apoptosis in primary APL blasts.
Materials and methods

Reagents
ATO was purchased from Sigma (St Louis, MO, USA). A 1 mmol/l stock solution was obtained by dissolving ATO in phosphatebuffered saline (PBS): the solution was diluted to working concentration immediately before use. A 100 mM stock solution of the MEK1 inhibitors PD98059 (2 0 -amino-3 0 -methoxyflavone; Cell Signaling Technology, Beverly, MA, USA) or PD184352 (2-[chloro-4-iodo-phenylamino]-N-cyclopropylmethoxy-3,4-difluoro-benzamide) kindly provided to us by Dr JS SeboltLeopold (Cancer Molecular Sciences, Pfizer Global Research & Development, Ann Arbor, MI, USA) was prepared in dimethyl sulfoxide (DMSO). These reagents are highly selective inhibitors of MEK1 phosphorylation and activation. 23, 24 The doses used by us of 1 or 2 mM for PD184352 and of 10, 20 or 40 mM for PD98059 were those that proved effective in vitro in leukemic cells as documented both by ourselves and other authors. [17] [18] [19] The doses of ATO hereby employed were selected based on the evidence that ATO, from concentrations of 0.5 to 2 mM upwards, has the capacity to induce apoptosis without differentiation in NB4 cells. These in vitro concentrations are within the range found in the plasma of patients receiving ATO treatment for APL and entering complete hematologic remission after such therapy. 25 
Cell lines and patient primary blasts
Selection of NB4 arsenic-resistant cell line (NB4-As R ). An arsenic-resistant NB4 subline named NB4-As R Paolo Lunghi 1 (PL1), hereafter referred to as NB4-As R , was derived from the NB4 cell line following the method described by Gianni et al.
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NB4-As R was obtained by treating parental cells with ATO 1 mM weakly and was maintained with the same dose. In the presence of high doses of ATO (1 mM), the NB4-As R grew, although at a reduced rate, while the parental cell line died. NB4-As R cells were also constantly grown in the presence of 1 mM ATO. In experiments examining the response of NB4-As R to ATO, the cells were first washed thoroughly to remove ATO from the media, and then cultured for 24 h in the media alone prior to initiating the experiment.
Human leukemia cell lines NB4 or NB4-As R in logarithmic growth were seeded at 1 Â 10 5 cells/ml of fresh RPMI 1640 medium (Gibco BRL,Grand Island, NY, USA), supplemented with 10% fetal calf serum, 2 mmol/l L-glutamine, penicillin G (100 U/ml), streptomycin (100 mg/ml) (Gibco BRL) and with or without the compounds described above, in a humidified atmosphere of 95% air/5% CO 2 .
The patients studied were affected by typical hypergranular APL (M3). Patients # 1 and # 2 were investigated at diagnosism and patient # 3 at the time of relapse. Patient # 3 relapsed after receiving ATRA þ idarubicin (AIDA regimen) 26 as front-line treatment. In all analyzed samples, the percentage of leukemic infiltration exceeded 80%. The disease-specific PML/RARa fusion transcript was detected in all cases by RT-PCR as described previously. 26 Peripheral blood was obtained after informed consent. Leukemia cells were isolated and enriched on Ficoll-Hypaque density gradients (Pharmacia LKB Biotechnology AB, Uppsala, Sweden), washed twice with calcium and magnesium-free PBS and cultured as described above. Cell number was determined by trypan blue dye exclusion. The presence of cell differentiation after treatment was evaluated by means of microscopic examination of May-Grunwald-stained cells and nitroblue tetrazolium (NBT, Sigma-Aldrich) reduction assay as described. 27 CD11b-positive cells were detected by flow cytometry as described, 27 using the corresponding FITC-conjugated antibodies that were purchased from Becton Dickinson, San José, CA, USA. All the experiments performed utilizing the NB4 and NB4-As R cell lines were carried out in duplicate and repeated at least three times.
Flow cytometry assay
Flow cytometry assay to evaluate cell cycle and apoptosis after in vitro treatment with PD98059, PD184352 and ATO was performed as described previously. 17 A FACSCalibur apparatus (Becton Dickinson) was utilized. Data were analyzed using FlowJo 3.4 software (Tree Star, San Carlos, CA, USA).
Mitochondrial transmembrane potential (DC m )
To investigate the changes in mitochondrial transmembrane potential that occur during apoptosis, the MitoLight apoptosis detection kit (Chemicon International Inc., Temecula, CA, USA) was used. Briefly, after 48 h of treatment, cells were incubated with MitoLight reagent for 20 min at 371C. After centrifugation, they were resuspended in incubation buffer and analyzed by fluorescence-activated cell sorter scanner. MitoLight emits a red fluorescence (MitoLight aggregates, high DC m ) when sequestered in the mitochondrial membrane of healthy cells detectable in the PI channel. In apoptotic cells with altered mitochondrial membrane potential, the dye in its monomeric form remains in the cytoplasm, emitting a green fluorescence (MitoLight monomers, low DC m ) detectable in the fluorescein isothiocyanate channel.
siRNA transfections
Prior to electroporation, NB4-As R cells were washed twice with serum-free Opti-MEM (Gibco BRL Paisley, UK) and resuspended to a final concentration of 8 Â 10 6 cells/ml in Opti-MEM (Gibco BRL). Subsequently, 0.5 ml of cell suspension was mixed either with 0.5 nmol of Smart pool double-stranded RNA oligonucleotides (siRNA) against MEK1 (M-003571) or nonspecific control siRNA (D-001206-13-05) obtained from Dharmacon Tech (Lafayette, Co, USA) and electroporated in a 0.4-cm cuvette using the Gene Pulser electroporation apparatus (Bio-Rad Laboratories Inc., Herculex, CA, USA) and using a single-pulse protocol (voltage 260 V and capacitance 1050 mF). At 48 h after transfection, cells were treated with ATO 1 mM for another 48 h. The cells were harvested for DC m , annexin V, sub-G1 DNA content detection and immunoblotting.
Molecular analysis
Cell lysis, immunoblotting, immunoprecipitation, and ERK immunoenzymatic assay were carried out as described. 17, 28, 29 For immunoprecipitation, the following antibodies were used: rabbit polyclonal anti-p44/p42 ERK, rabbit polyclonal anti-Bad and rabbit polyclonal anti-phospho-Bad, all provided by Cell Signaling Technology Beverly, MA, USA. For immunoblotting, the following antibodies were used: rabbit polyclonal anti-p44/ p42 ERK, rabbit polyclonal anti-phospho-p44/42 ERK (Thr202/ Tyr204), rabbit polyclonal anti-MEK1/2, rabbit polyclonal antiphospho-Bad, rabbit polyclonal anti-Bad, mouse monoclonal anti-Bax and rabbit anti-Bcl-xL all provided by Cell Signaling Technology, mouse monoclonal anti-Bcl-2 clone 124 (Upstate Biotechnology, Lake Placid, NY, USA), mouse monoclonal PARP (F2) (Santa Cruz Biotechnology, Santa Cruz, CA, USA); goat polyclonal anti-human actin (Santa Cruz Biotechnology); goat
For coimmunoprecipitation analysis, lysates were precleared with the appropriate control IgG (normal rabbit IgG, Santa Cruz Biotechnology) together with Agarose A/G beads (Santa Cruz). Subsequently, the lysates (500 mg) were incubated with 2-4 mg of primary antibody at 41C for 2 h. Agarose A/G beads (Santa Cruz) were added and samples were incubated at 41C overnight. Samples were washed four times and the protein/bead mixture was denatured at 951C for 5 min and then loaded onto 15% SDS-polyacrylamide gels. Blots were subjected to Western blotting as described.
Statistical analysis
For multiple comparisons, a statistical analysis was performed using analysis of variance for repeated measurements followed by a Tukey-Kramer or Dunnet post-tests.
Synergism, additive effects and antagonism were assessed using the Chou-Talalay method 30 and Calcusyn software (Biosoft, Ferguson, MO, USA). Briefly, the dose-effect curve for each drug alone was determined based on the experimental observations using the median-effect principle; the combination index (CI) for each experimental combination was then calculated according to the following equation: CI ¼ (Ac)/ (As) þ (Bc)/(Bs) þ (Ac) (Bc)/(As) (Bs), where (Ac) and (Bc) correspond to the concentrations of drugs A and B that have x effect when used in combination and (As) and (Bs) correspond to the concentrations of drugs A and B able to produce, alone, the same magnitude of effect. When CI ¼ 1, this equation represents the conservation isobologram and indicates additive effects. CI values less than 1.0 indicate a more than expected additive effect (synergism). CI values more than 1.0 indicates an antagonistic effect.
Results
MEK1 inhibition enhances ATO-mediated apoptosis both in NB4 and in NB4-As R cells, and in fresh APL primary blasts
We first studied the effect on cell growth inhibition in NB4 and NB4-As R cell lines treated with PD and/or ATO. After 48 h of treatment, the combination of PDs (PD98059 40 mM or PD184352 1 mM) and ATO 1 mM significantly (Po0.001) decreased cell growth compared to PDs or ATO alone in both cell lines (Figure 1a and b). At later times (72-96 h), the combination of the two agents did not reach statistical significance in parental NB4 because of cell death due to ATO (1 mM)-induced apoptosis (data not shown).
We therefore studied the effect of PDs, ATO or both agents in combination on apoptosis in NB4, NB4-As R leukemic cells and fresh APL primary blasts from patients.
After 72 h of treatment, we observed that the combination of MEK1 inhibitors (PD98059 40 mM or PD184352 1 mM) with ATO (ATO 1 mM) strikingly increased the percentage of sub-G1 apoptotic cells induced by ATO alone in both parental and NB4-As R cells (Figure 2a ). These data were confirmed by the exposure of phosphatidylserine on the outer leaflet of the plasma membrane (data not shown). Similar results were obtained in both cell lines treated with lower doses of PD98059 (20 and 10 mM) (data not shown).
Changes in mitochondrial transmembrane potential (DC m ) are a critical step in cells undergoing apoptosis, regardless of the death signal. Therefore, we compared DC m in ATO-or PD þ ATO-treated cells by using a mitochondrion-specific dye, MitoLight, which displays a green to red spectral shift proportional to DC m (see Materials and methods). The combined treatment with PD184352 and ATO strikingly potentiated loss of DC m induced by ATO in both cell lines (Figure 2b ), indicating that the dual treatment affects the mitochondria apoptotic pathway. Similar results were observed with PD98059 (data not shown).
Finally, to characterize the pharmacologic interactions between PD184352 and ATO more rigorously and over a range of drug concentrations, median dose effect analysis was used (see Materials and methods). When apoptosis by sub-G 1 DNA content or annexin V/PI staining was measured after 48 h of drugs exposure, CI values considerably less than 1.0 were obtained in arsenic-resistant cells and to a lesser extent in the parental NB4 cells, corresponding to highly synergistic interactions in both NB4-As R cells and parental cells (Figure 2c ). Thus, these agents appear to synergize for the induction of apoptosis primarily in arsenic-resistant and also in parental NB4 cells. We next studied the apoptotic effect of the combined treatment in fresh APL primary blasts. Interestingly, the percentage of sub-G1 apoptotic cells in patients (cases # 1, # 2 and # 3) treated for 48 h with PD98059 40 mM and ATO at concentrations of 1 or 2 mM -concentrations that are usually achieved in the plasma of ATO-treated APL patients 25 -was greater (two-or three-fold more) than that found after treatment with ATO 1 or 2 mM alone (Supplementary Figure 2) . These data were confirmed by the exposure of phosphatidylserine on the outer leaflet of the plasma membrane (data not shown).
The treatment with PD98059 alone showed a low increase of cell death in patient # 2, while a stronger apoptosis induction was observed in patients # 1 and # 3 (relapse) (Supplementary Figure 2) .
Moreover, no significant signs of cell differentiation were observed by microscopic examination of May-Grunwaldstained cells, NBT test and CD11b-positive cell count during this combined therapy (data not shown). Taken together, these findings showed that MEK1 inhibitors and ATO strongly cooperate in their activation of apoptosis effectors.
PD treatment inhibits ATO-mediated ERK1/2 activation and increases PARP fragmentation in NB4 and NB4-As R cell lines as well as in fresh APL primary cells
In order to explain the molecular effectors involved in growth control and apoptosis, we first studied the kinetics of ERK1/2
Figure 1
Combined effects of ATO and MEK1 inhibitors on cell growth in the NB4 and in NB4-As R leukemic cell line. The cells NB4 (a) and NB4-As R (b) seeded at 1 Â 10 5 cells/ml were pretreated for 3 h with MEK1 inhibitors PD98059 40 mM or PD184352 1 mM, and then incubated with ATO. Each value represented the mean7s.d. of at least three independent experiments. Cell count was determined using the trypan blue dye exclusion method. AS ¼ ATO.
MEK1 inhibition and arsenic trioxide in APL P Lunghi et al activity and poly(ADP-ribose) polymerase PARP fragmentation that reflects increased apoptosis 31 in parental and arsenicresistant NB4 cells treated with PD and ATO.
In NB4 cells, the analysis of ERK1/2 activity demonstrated that ATO induced, in a dose-dependent manner, a sustained kinase activity that was clearly evident after 15 min, 1 h (data not . After 48 h, apoptosis was measured by sub-G1 DNA content. CI plots was then generated using the Calcusyn software (symbols represent actual data points for the combination). CI less than 1.0 indicates synergism; CI ¼ 1.0 indicates additive effect; CI more than 1.0 indicates antagonistic effect. AS ¼ ATO. (Figure 3a) . At a later time point (48 h), the ATO-mediated ERK1/2 activity was still detectable, although at very low levels (Figure 3a) . Even in the NB4-As R , ATO 1 mM strongly increased ERK1/2 activity and the activation of these mitogen-activated protein kinases (MAPK) was clearly evident after 24 and 48 h of ATO treatment (Figure 3b ).
MEK1 inhibition and arsenic trioxide in APL
The treatment with MEK1 inhibitors downmodulated the steady level of ERK activity and prevented the ATO-mediated ERK1/2 activation in both cell lines (Figure 3a and b) .
Moreover, the combined treatment also led to an increased fragmentation of PARP that occurred earlier in arsenic-resistant cells (24 h) as compared to parental cells (48 h) (Figure 3a and b).
Since ATO is able to enhance the activity of ERK in both NB4-As R and parental NB4 cell lines, we decided to compare its activity in these cell lines by means of an immunoenzymatic MAP kinase assay. Interestingly, ERK1/2 activity was greatly enhanced in the NB4-As R as compared to parental cells (2.7-and 24-fold increase after 24 and 48 h of ATO treatment, respectively) as shown in Figure 3c . Moreover, in NB4-As R treated with ATO, similar levels of ERK activity were observed at 24 and 48 h, whereas a significant decrement in activity occurred after 72 h. In parental NB4 cell lines, the decrement in this MAPK activity was clearly evident as from 48 h (Figure 3c) .
Subsequently, fresh blasts from APL patients were treated with ATO 0.25, 1 and 2 mM for 24 h with or without PD98059 pretreatment. In APL primary blasts, ATO induced a strong 
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increase of ERK1/2 activity in a dose-dependent manner; PD98059 pre-treatment was able to inhibit the ATO-mediated ERK1/2 activation, leading to increased PARP fragmentation (Supplementary Figure 3) . Finally, to determine the contribution of MEK-ERK pathway activation in mediating ATO resistance, the MEK1 mRNA was selectively knocked down by means of specific double-stranded RNA oligonucleotides (siRNA). Recently, siRNAs have been shown to achieve a high degree of specificity with low toxicity also in mammalian cells acting through a degradative chain reaction catalyzed by the activation of a cellular RNAdependent RNA polymerase. 32, 33 Transfection of MEK1 siRNA, but not the nonspecific control siRNA, led to the decrease of MEK1 in NB4-As R without affecting the levels of the unrelated protein actin (Figure 4a ). When NB4-As R were treated with ATO, an increased PARP fragmentation and an important shift in green fluorescence, indicating loss of DC m , was observed in cells transfected with MEK1 siRNA relative to cells transfected with control siRNA (Figure 4a and b) . The apoptotic nature of the cell death triggered by ATO after the disruption of MEK-ERK pathway was confirmed by the exposure of phosphatidylserine on the outer leaflet of the plasma membrane and by demonstration of a decrease in the DNA content to sub-G 1 levels (data not shown). These findings indicate that the MEK-ERK pathway is determinant in the development of ATO resistance.
ATO-mediated ERK1/2 activation induces phosphorylation at Ser112 of the endogenous proapoptotic Bad protein in APL cells
Recent studies have demonstrated the involvement of MEK-ERK kinases upstream of Bad phosphorylation at serine 112 in promoting cell survival. [34] [35] [36] [37] The proapoptotic function of Bad is characterized by its ability to heterodimerize with Bcl-2 and Bcl-xL, blocking the antiapoptotic function of these proteins. 38, 39 Phosphorylation at Ser112, Ser136 or Ser155 inhibits the function of Bad. We then investigated phosphorylation at Ser112 and the expression of the proapoptotic Bad protein after ATO treatment, both with and without MEK1 inhibitors in NB4, NB4-As R and APL primary cells. Immunoblotting analysis of cellular extracts from the same experiments described above showed that, in NB4 and NB4-As R cell lines as well as in APL primary cells, ATO-mediated ERK1/2 activation was related to an increased phosphorylation at Ser112 of Bad ( Figure 5 and Supplementary Figure 5) . Interestingly, after ATO treatment, the NB4-As R cells showed a larger increment of Bad phosphorylation at Ser112 (2.4-fold more) than NB4 ( Figure 5 ) that correlated well with the stronger ERK activity found in this cell line (Figure 3c ). The downmodulation of ERK1/2 activity by MEK1 inhibitors resulted in decreased phosphorylation of Bad in NB4, NB4-As R cell lines as well as in APL primary cells ( Figure 5 and Supplementary Figure 5) . Interestingly, the PD-mediated downmodulation of phospho-Bad completely restored the sensitivity to ATO treatment in NB4-As R cells, leading to a strong increment of fragmented PARP ( Figure 5 ). The expression of the Bcl-2 family proteins, Bcl-xL, Bcl-2 and Bax, involved in apoptotic pathways were also studied. The death antagonists Bcl-2 and Bcl-xL proteins were expressed at similar levels in untreated parental or NB4-As R ( Figure 5 ). After 24 h of treatment, we did not observe significant Bcl-2 degradation in NB4-As R or NB4 cells treated with 1 mM of ATO ( Figure 5) ; conversely, both cell lines nearly doubled the expression of BclxL ( Figure 5 ). Neither MEK1 inhibitors alone nor their combination with ATO 1 mM were able to induce significant degradation of the Bcl-2 protein ( Figure 5) ; conversely, MEK1 inhibitors significantly inhibited the Bcl-xL increased protein expression mediated by ATO in both cell lines ( Figure 5 ). The base-line level of the death agonist Bax protein was significantly greater in NB4 (1.7-fold more) than in NB4-As R . After ATO or PD þ ATO treatment, Bax expression nearly doubled in both cell lines. Together, our results showed that the more marked difference between these two lines was the status of ERK and Bad phosphorylation after ATO treatment.
ATO triggers dissociation of Bcl-xL and Bcl-2 from Bad in APL cells
We proceeded to investigate whether the phosphorylation status of Bad affected its capacity to associate with death antagonists Bcl-xL and Bcl-2 in NB4-As R and parental NB4 cell lines. To this end, we examined the constitutive and ATO-induced protein-protein interactions of Bad pathway components using co-immunoprecipitation. Preliminary studies confirmed that the Bad antibody effectively precipitated Bad (data not shown). In untreated NB4-As R and NB4 cells, we observed a significant binding of Bcl-xL and Bcl-2 proteins to Bad immunoprecipitates, indicating the presence of endogenous Bad/Bcl-xL or Bad/Bcl-2 heterodimers ( Figure 6 ). The levels of Bcl-xL and Bcl-2 that coimmunoprecipitated with Bad were comparable in both cell lines ( Figure 6 ). After treatment with ATO, the binding of Bcl-xL and Bcl-2 to endogenous Bad sharply decreased in both cell lines ( Figure 6 ). Interestingly, after ATO treatment, we observed a reduced amount of Bad/Bcl-xL and Bad/Bcl-2 heterodimers in NB4-As R compared to NB4 ( Figure 6 ); this behavior correlated well with the different phosphorylation status of Bad in these two lines treated with ATO ( Figure 5) .
In order to examine the amounts of free Bcl-xL and Bcl-2 that did not co-immunoprecipitate with Bad, the supernatants after Bad immunoprecipitation were Western blotted for Bcl-xL and 
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Bcl-2. The amount of free Bcl-xL in untreated NB4-As R or NB4 cells was comparable, but after ATO treatment, we observed a stronger increment of free Bcl-xL in NB4-As R compared to parental NB4 (3-vs 1.7-fold increase compared to the control, respectively) ( Figure 6 ). Interestingly, even if the total amount of Bcl-xL was comparable in both cell lines (Figure 5 ), free Bcl-xL was nearly doubled in NB4-As R compared to NB4 in ATOtreated cells (Figure 6 ). In untreated cells, the amount of free Bcl-2 was more evident in NB4 than in NB4-As R . As per free Bcl-xL, a stronger increment of free Bcl-2 was observed in NB4-As R compared to NB4 (2.6 vs 1.4 compared to the control) after ATO treatment; the amount of free Bcl-2 was higher in NB4-As R . The treatment with MEK1 inhibitors was able to downmodulate ERK1/2 and Bad phosphorylation (Figure 5 ), leading to a strong ATO induces the phosphorylation of Bad at serine 112. NB4-As R and parental NB4 cell lines were pretreated with either DMSO (vehicle) or MEK1 inhibitors (PD98059 40 mM or PD184352 1 mM) for 3 h and then treated with 1 mM of ATO for 24 h. Immunoblots show cleaved PARP fragments, ERK1 and ERK2 dual phosphorylation and expression, Bad phosphorylation at Ser112 and Bad expression, Bcl-xL, Bcl-2 and Bax expression after treatment. For the analysis of Bad phosphorylation, lysates were subsequently immunoprecipitated with the anti-Bad antibody, and the immunoprecipitated samples were subjected to 15% SDS-PAGE, followed by Western blotting with the anti-phospho-Ser-112-Bad antibody. The filters were then stripped and reprobed with the anti-Bad antibody. To evaluate the relative levels of Bad phosphorylation, Bcl-xL, Bcl-2 and Bax expression, bands were subjected to densitometric scanning using the TINA 2 software.
Figure 6
ATO triggers dissociation of Bcl-xL and Bcl-2 from Bad in NB4-As R and in NB4 cell lines. NB4-As R and parental NB4 cell lines were pretreated with either DMSO (vehicle) or PD184352 1 mM for 3 h and then treated with 1 mM of ATO for 24 h. Lysates were subsequently immunoprecipitated with the anti-Bad antibody, and the immunoprecipitates were analyzed by Western blotting with anti-Bcl-xL or antiBcl-2 antibodies to detect the amount of Bcl-xL and Bcl-2 proteins that associated with Bad. The supernatants after Bad immunoprecipitation were also analyzed to determine the amount of Bcl-xL and Bcl-2 that did not associate with Bad. Bands were subjected to densitometric scanning using the TINA 2 software. Bad levels in the immunoprecipitates are shown as control. Immunoblots are representative of at least two independent experiments. MEK1 inhibition and arsenic trioxide in APL P Lunghi et al increment of Bcl-xL and Bcl-2 protein that immunoprecipitated with Bad in both cell lines ( Figure 6 ).
Discussion
In this report, an arsenic-resistant NB4 subline, NB4-As R , was characterized and used to demonstrate that ATO and MEK1 inhibitors synergize to induce apoptosis. Resistance to the apoptotic effect of ATO was primarily linked to an altered activity of the Ras-MAPK pathway in response to this drug. In fact, also the parental NB4 showed, under ATO exposure, a significant increment in prosurvival ERK activity, although to a lesser extent as compared to NB4-As R (Figure 3c ). Interestingly, similar effects were observed in primary APL blasts from patients treated in vitro with ATO (Supplementary Figure 3) .
The activation of the MEK/ERK pathway, which provides a survival signal against stress-induced apoptosis is not only reported as a result of ATO exposure 40, 41 but also after stimulation by stress factors or inflammatory cytokines, 42 and subsequent to treatment with the chemotherapeutic drugs paclitaxel 43 and cisplatin, 44, 45 or after ionizing and UV irradiation. [46] [47] [48] Both in the parental and in the NB4-As R cell lines as well as in primary APL blasts, the ATO-mediated ERK1/2 activation led to an increased phosphorylation at Ser112 of the proapoptotic Bad protein. Moreover, under ATO exposure, the higher ERK activity in NB4-As R than in the parental NB4 cells correlated well with the stronger increment of Bad phosphorylation status at Ser112 observed in NB4-As R ( Figure 5 ). To date, the only known function of the BH3-only protein Bad is to bind Bcl-2 family proteins Bcl-2 and Bcl-xL, thereby blocking the antiapoptotic action of these proteins by preventing them from binding Bax/Bak. 38, 39, 49 The apoptotic activity of Bad is clearly determined by its phosphorylation status and only nonphosphorylated Bad heterodimerizes with Bcl-xL or Bcl-2, neutralizing their protective effect and promoting cell death. 49 To better understand Bad's role in this experimental model, we analyzed the total protein levels of Bcl-xL and Bcl-2 and their interaction with endogenous Bad. The death agonist Bax was also studied. Both in NB4 and in NB-As R cell lines, the steady levels of Bcl-2 and Bcl-xL were comparable, whereas the Bax expression was higher in parental (1.7-fold more) than in NB4-As R . At the earliest events, in response to ATO treatment, both cell lines increased the protein levels of Bcl-xL and Bax (a nearly two-fold increase compared to the control), whereas no significant modulation in the Bcl-2 protein was observed ( Figure 5 ). This was consistent with previous reports, which showed that Bcl-2 degradation did not occur in NB4 cells treated with 1 or 2 mM of ATO. 50, 51 Moreover, our findings that the ATO-induced upregulation of Bcl-xL was mediated by MEK/ ERK pathway are in line with previous reports showing an MEKdependent regulation of Bcl-2 family proteins. [52] [53] [54] [55] Interestingly, the treatment with MEK1 inhibitors blunted the ATO-mediated Bcl-xL upregulation both in parental and in NB4-As R cell lines ( Figure 5) .
Under ATO exposure, a more marked hyperphosphorylation of Bad took place in arsenic-resistant cells as opposed to parental cells, leading to an enhanced amount of free Bcl-xL and Bcl-2 capable of interacting with Bax/Bak proteins, thus favoring ATO resistance in the NB-As R cell line. Interestingly, after ATO treatment, a more slowly migrating Bcl-xL band on immunoblots of supernatants was observed after Bad immunoprecipitation in parental but not in arsenic-resistant cells, suggesting that posttranslational modifications of this protein occur only in the NB4 cell line (Figure 6 ). It has been demonstrated that the treatment with microtubule-targeted agents including paclitaxel, vincristine, vinblastine, colchicines and nocodazole or with DNAdamaging antineoplastic agents such as cisplatin and etoposide results in phosphorylation or in deamidation, respectively, of Bcl-xL protein; [56] [57] [58] [59] [60] both phosphorylation and deamidation alter Bcl-xL migration's during SDS-PAGE and have been shown to inhibit its antiapoptotic activities. 56, 59 Further investigation will be necessary to determine which Bcl-xL post-translational modifications occurs in ATO-treated cells and their roles in drug resistance.
Pretreatment with MEK1 inhibitors strongly inhibited ERK and Bad phosphorylation in APL cells, enhancing apoptosis in ATOtreated NB4 and in primary APL cells, and completely restoring sensitivity to ATO in the NB-As R cell line. Taken together, these results suggest that the Bad protein plays a pivotal role in determining the cell's susceptibility to drug-induced apoptosis and that compounds which affect its phosphorylation, such as MEK1 inhibitors PD98059 or PD184352, could be used in combination with existing therapies. 61, 62 Accordingly, in BxPc3 tumors that had regressed in response to treatment with the MEK1 inhibitor PD184352, reduced phosphorylation of the serine 112 site on Bad was demonstrated ex vivo by SeboltLeopold. 63 The compound PD184352 (now designated CI-1040) was formulated for use in vivo per os 24, 63 and clinical trials are currently in progress for the purpose of studying its efficacy in advanced forms of cancer, lymphoma and leukemia refractory to treatment. 64 Interestingly, PD184352 even at 10 mM did not inhibit any protein kinase other than MEK1, as detected by an investigation of a large panel of kinases. 65 Recently, we demonstrated that in leukemia cells, the combined treatment with MEK1 inhibitors and ATO promotes the up-regulation of p53AIP1 protein (p53-regulated apoptosisInducing protein 1) via p73 activation. 66 p53AIP1, a primary effector gene of wild-type p53 and TAp73-induced apoptosis, 67, 68 interacts with Bcl-2 proteins at the mitochondrial membrane and the overexpression of Bcl-2 blocks the downregulation of DC m and the proapoptotic activity of p53AIP1. 69 Together, these findings support a model in which the p73-p53AIP1 apoptotic pathway is potentiated by Bad phosphorylation pathway through the increased capacity of Bad, after MEK 1 inhibition, to associate with Bcl-xL and Bcl-2, thereby blocking their antiapoptotic functions. Together with our results, this may encourage to design clinical trials aimed at investigating the efficacy of ATO, currently considered the treatment of choice for relapsed APL, 6 in combination with MEK1 phosphorylationblocking agents.
Recently, it has been demonstrated that the combined inhibition of MAPK and phosphatidylinositol 3 kinase (PI3K) pathways, the two major protein kinase pathways involved in Bad phosphorylation, markedly increased the PI3K inhibitionmediated apoptosis in leukemia cells, 70 suggesting that multiple signal transduction pathways interact to regulate apoptosis in leukemic cells; both MAPK and PI3K pathways are also involved in the regulation of other downstream antiapoptotic members of the IAP family 71, 72 and can synergize to induce cell survival and cellular transformation. 73 Moreover, the activation of PI3K contributes for MEK1-responsive growth and survival. 74 These findings together with our results provide a rationale background to further investigate the possible role of PI3K in ATO resistance and to determine whether the combined inhibition of MAPK and PI3K pathways is more effective than single targeting signal transduction pathway in increasing the antileukemic effect of ATO.
Recently, transient transfection of wild-type PML-RARa into nonhemopoietic CHO cells has been reported to cause little or no enhancement of cell death in response to ATO. 75 This finding is in agreement with the fact that the effects of ATO are cell type and dose specific. 76 Accordingly, the MEK1-ERK pathway may have opposite functions and may modulate cell life or death depending on the characteristics of the stimuli and the cell type involved, as well as on the doses utilized. 77 Indeed, PD184352 cannot inhibit any protein kinase other than MEK1, 65 and the antitumoral effects of MEK1 inhibition are well established and tightly consolidated by the reproducible results obtained by different groups. [17] [18] [19] [20] [21] [22] 63, 78 In conclusion, our results provide an experimental basis for combined or sequential treatment with MEK1 inhibitors and ATO in APL.
